Skip to search formSkip to main contentSkip to account menu

safinamide

Known as: (S)-2-((4-(3-fluorobenzoxy)benzyl)amino)propanamide, 2-(4-(3-fluorobenzyloxy)benzylamino)propionamide 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (2)

AlanineBenzylamines

Narrower (4)

FCE 26743FCE 28073NW-1015PNU 151774E
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor
Review
2012
Review
2012
Managing the patient with newly diagnosed Parkinson disease
The treatment of early Parkinson disease (PD) is generally symptomatic, although therapy that also offers neuroprotection in… 
2011
2011
Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium…
We recently reported that merging key structural pharmacophores of the anticonvulsant drugs lacosamide (a functionalized amino… 
2010
2010
Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B.
Two polymorphs of safinamide {systematic name: (2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide}, C(17)H(19)FN(2)O(2), a… 
2007
2007
Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase.
Safinamide, (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide methanesulfonate, which is in phase III clinical trials as an anti… 
Review
2007
Review
2007
Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Merck Serono SA (formerly Serono), under license from Newron Pharmaceuticals SpA (following its acquisition of the rights from… 
Review
2006
Review
2006
New pharmacologic horizons in the treatment of Parkinson disease
Many of the motoric features that define Parkinson’s disease (PD) result primarily from the loss of dopaminergic neurons of the… 
2006
2006
Bioassay of Safinamide in Biological Fluids of Humans and Various Animal Species
Summary This paper describes three methods to bioassay safinamide (CAS 133865-89-1) in biological fluids of humans and laboratory… 
Review
2002
Review
2002
Novel anticonvulsant medications in development
Epilepsy is currently the most prevalent neurological disorder worldwide. Pharmacological therapy remains the cornerstone of… 
Review
2001
Review
2001
Safinamide (Newron Pharmaceuticals).
Safinamide (formerly PNU-151774E), a sodium and calcium channel modulator that also inhibits monoamine oxidase B (MAOB), is under… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)